Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus

Journal of Virological Methods

Volumn 156, Issue 1-2, 2009, Pages 77-83

  Dalstein, Véronique ^a   Merlin, Sandra ^b   Bali, Corinne ^b   Saunier, Maëlle ^c   Dachez, Roger ^d   Ronsin, Christophe ^b  

^a HÔPITAL MAISON BLANCHE   (France)

^b Laboratoire L C L   (France)

^c UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^d CEF (centre d'exploration fonctionelle)   (France)

Author keywords

DNA chip; HPV genotyping; Human papillomavirus; Hybrid capture 2; Linear Array; PapilloCheck test

Indexed keywords

VIRUS DNA;

ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; GENOTYPE; NONHUMAN; PRIORITY JOURNAL; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS;

CERVIX UTERI; DNA, VIRAL; FALSE POSITIVE REACTIONS; FEMALE; GENOTYPE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; VAGINAL SMEARS;

HUMAN PAPILLOMAVIRUS;

EID: 59849122606     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2008.11.002     Document Type: Article

References (31)

1. Arbyn M., Sasieni P., Meijer C.J., Clavel C., Koliopoulos G., and Dillner J. Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24 (2006) S78-S89
2. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55 (2002) 244-265
3. Castle P.E., Schiffman M., Burk R.D., Wacholder S., Hildesheim A., Herrero R., Bratti M.C., Sherman M.E., and Lorincz A. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 1394-1399
4. Castle P.E., Solomon D., Schiffman M., and Wheeler C.M. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J. Natl. Cancer Inst. 97 (2005) 1066-1071
5. Coutlee F., Rouleau D., Petignat P., Ghattas G., Kornegay J., Schlagg P., Boyle S., Hankins C., Vézina D., Cote P., Macleod J., Voyer H., Forest P., Walmsley S., and Franco E.L. Enhanced detection and typing of human papillomavirus DNA in anogenital samples with PGMY primers and the Linear Array HPV genotyping test. J. Clin. Microbiol. 44 (2006) 1998-2006
6. Cuzick J., Terry G., Ho L., Hollingworth T., and Anderson M. Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. Br. J. Cancer. 69 (1994) 167-171
7. Dunn S.T., Allen R.A., Wang S., Walker J., and Schiffman M. DNA extraction: an understudied and important aspect of HPV genotyping using PCR-based methods. J. Virol. Methods 143 (2007) 45-54
8. Ferlay, J., Bray, F., Pisani, P., Parkin, D.M., 2005. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide, version 2.0. IARC Cancer Base No. 5. IARC Press, Lyon, France (Online). http://www-depdb.iarc.fr/globocan/GLOBOframe.htm.
9. Gillio-Tos A., De Marco L., Ghisetti V., Snijders P.J., Segnan N., Ronco G., and Merletti F. Human papillomavirus typing with GP5+/6+ polymerase chain reaction reverse line blotting and with commercial type-specific PCR. J. Clin. Virol. 36 (2006) 126-132
10. Gravitt P.E., Peyton C.L., Apple R.J., and Wheeler C.M. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J. Clin. Microbiol. 36 (1998) 3020-3027
11. Hesselink A.T., Bulkmans N.W., Berkhof J., Lorincz A.T., Meijer C.J., and Snijders P.J. Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J. Clin. Microbiol. 44 (2006) 3680-3685
12. Ho G.Y., Burk R.D., Klein S., Kadish A.S., Chang C.J., Palan P., Basu J., Tachezy R., Lewis R., and Romney S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J. Natl. Cancer Inst. 87 (1995) 1365-1371
13. Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R., Rush B.B., Glass A.G., and Schiffman M. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. Natl. Cancer Inst. 97 (2005) 1072-1079
14. Kjaer S.K., van den Brule A.J., Paull G., Svare E.I., Sherman M.E., Thomsen B.L., Suntum M., Bock J.E., Poll P.A., and Meijer C.J. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 325 (2002) 572-576
15. Muldrew K.L., Beqaj S.H., Han J., Lum S.H., Clinard V., Schultenover S.J., and Tang Y.W. Evaluation of a Digene-recommended algorithm for human papillomavirus low-positive results present in a "retest zone". Am. J. Clin. Pathol. 127 (2007) 97-102
16. Munoz N., Bosch F.X., de Sanjose S., Horrero R., Castellsagué X., Shah K.V., Snijders P.J., and Meijer C.J. Epidemiological classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348 (2003) 518-527
17. Munoz N., Castellsagué X., Berrington de Gonzalez A., and Gissmann L. HPV in etiology of human. Vaccine 24 (2006) S3-S10
18. Peyton C.L., Schiffman M., Lorincz A.T., Hunt W.C., Mielzynska I., Bratti C., Eaton S., Hildesheim A., Morera L.A., Rodriguez A.C., Herrero R., Sherman M.E., and Wheeler C.M. Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J. Clin. Microbiol. 36 (1998) 3248-3254
19. Plummer M., Schiffman M., Castle P.E., Maucort-Boulch D., Cosette M., and Wheeler C.M. A 2-Year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. JID 195 (2007) 1582-1589
20. Sabol I., Salakova M., Smahelova J., Pawlita M., Schmitt M., Gasperov N.M., Grce M., and Tachezy R. Evaluation of different techniques for identification of human papillomavirus types of low prevalence. J. Clin. Microbiol. 46 (2008) 1606-1613
21. 10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5683 young women in Guanacaste, Costa Rica. J. Clin. Microbiol. 45 (2007) 1447-1454
22. Sandri M.T., Lentati P., Benini E., Dell'Orto P., Zorzino L., Carozzi F.M., Maisonneuve P., Passerini R., Salvatici M., Casadio C., Boveri S., and Sideri M. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J. Clin. Microbiol. 44 (2006) 2141-2146
23. Seme K., Fujs K., Kocjan B.J., and Poljak M. Resolving repeatedly borderline results of Hybrid Capture 2 HPV DNA Test using polymerase chain reaction and genotyping. J. Virol. Methods 134 (2006) 252-256
24. Stevens M.P., Rudland E., Garland S.M., and Tabrizi S.N. Assessment of MagNA pure LC extraction system for detection of human papillomavirus (HPV) DNA in PreservCyt samples by the Roche AMPLICOR and LINEAR ARRAY HPV tests. J. Clin. Microbiol. 44 (2006) 2428-2433
25. Stevens M.P., Garland S.M., Rudland E., Tan J., Quinn M.A., and Tabrizi S.N. Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J. Clin. Microbiol. 45 (2007) 2130-2137
26. Terry G., Ho L., Londesborough P., Cuzick J., Mielzynska-Lohnas I., and Lorincz A. Detection of high-risk HPV types by the hybrid capture 2 test. J. Med. Virol. 65 (2001) 155-162
27. 10 line probe assay. J. Clin. Microbiol. 40 (2002) 979-983
28. van Hamont D., van Ham M.A., Bakkers J.M., Massuger L.F., and Melchers W.J. Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the Roche linear array HPV genotyping test. J. Clin. Microbiol. 44 (2006) 3122-3129
29. Vernon S.D., Unger E.R., and Williams D. Comparison of human papillomavirus detection and typing by cycle sequencing, line blotting, and hybrid capture. J. Clin. Microbiol. 38 (2000) 651-655
30. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J., Peto J., Meijer C.J., and Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189 (1999) 12-19
31. Wang-Johanning F., Lu D.W., Wang Y., Johnson M.R., and Johanning G.L. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis. Cancer 94 (2002) 2199-2210